Medtronic MDT recently announced two ... slim X2 became the first AID system to integrate with Abbott’s new FreeStyle Libre 2 Plus sensor. The breakthrough development enables t:slim X2 users ...

which is part of the Medtronic Cardiovascular Portfolio. "The potential of Affera is limitless. We will continue to fulfill our commitment to innovation, including new indications, to advance ...

Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...

Baxter will share an update on Hurricane Helene’s impact, while Medtronic will likely discuss a new pulsed field ablation ...

New features, especially with regard to lead design and geometry, characterize the system. Specifically Medtronic redesigned ... of reed-switch to a Hall sensor. Furthermore, it has developed ...

Users were told to contact Medtronic if they experience significantly reduced battery life to determine whether replacement is necessary. The new alert updates a previous one issued in July.

Increased competition from Medtronic and Abbott Laboratories ... at the two different types of revenue - hardware, as well as sensor and other revenue. While hardware revenue is continuing ...

Shares of NYSE:MDT opened at $90.01 on Monday. Medtronic has a 12 month low of $68.84 and a 12 month high of $91.49. The business has a 50-day moving average of $87.74 and a two-hundred day moving ...

Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their recent ...

Medtronic announced today that it appointed Dr. Matthew Kroh as chief medical officer for Advanced and General Surgical Technologies.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

which is part of the Medtronic Cardiovascular Portfolio. "The potential of Affera is limitless. We will continue to fulfill our commitment to innovation, including new indications, to advance ...